Business
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster presentations at the upcoming European Lung Cancer Congress (ELCC) 2025 Scientific Committee and Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025, to be held in Paris, France from March 26
About this update from Bioatla, Inc.
[{"type":"image","alt":"BioAtla, Inc.","displaySize":"","headline":null,"caption":"BioAtla, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":164,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/add243e63c7c504df7517ccebf39d348"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z8G3hxIezptosVzATIpKBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/add243e63c7c504df7517ccebf39d348","width":164,"height":75}},"lazy":false},{"type":"text","content":"SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster presentations at the upcoming European Lung Cancer Congress (ELCC) 2025 Scientific Committee and Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025, to be held in Paris, France from March 26–29, 2025 and in Scottsdale, AZ from March 27–29, 2025, respectively.","length":569,"tagName":"p"},{"type":"text","content":"Presentation Details:","length":21,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:18%;width:18%;min-width:18%;vertical-align:top;","val":[{"type":"text","content":"Venue:","length":6,"tagName":"p","attribs":{}}]},{"style":"max-width:82%;width:82%;min-width:82%;","val":[{"type":"text","content":"ELCC 2025","length":9,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Title:","length":6,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Exploratory Analysis of Overall Survival among Non-Small Cell Lung Cancer (NSCLC) Patients with Mutated KRAS in a Phase 2 Trial of Mecbotamab Vedotin (CAB-AXL-ADC)","length":163,"tagName":"p"}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Presenter:","length":10,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Karen Reckamp (Los Angeles, CA, United States of America)","length":62,"tagName":"p"}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Poster Number:","length":14,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"98P","length":3,"tagName":"p"}]}]},{"val":[{"style":"vertical-align:to...